Q-omics provides the consensus-scored LINC01117 profile across patient tissues and cancer cell-line models. LINC01117 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01117 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, LINC01117 RNA expression shows 15,568 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where LINC01117 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01117 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01117 survival associations across molecular data types. LINC01117 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01117 RNA expression–survival associations across cancer types. High LINC01117 expression shows unfavorable associations in KIRP, UVM, LUAD and ACC, but favorable associations in KIRC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01117 RNA expression.
This table summarizes LINC01117 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01117. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01117 shows lower tumor expression in KICH and higher tumor expression in HNSC, BRCA, LIHC, LUSC and KIRC. The HNSC box plot shows higher LINC01117 RNA expression in tumor versus normal tissue (log2 FC = +1.476, t-test p < 0.001).
This table shows molecular features associated with LINC01117 in patient tissues and cancer cell lines. In patient samples, LINC01117 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
